碱性成纤维细胞生长因子治疗放射性肠炎的临床研究

Basic fibroblast growth factor in treatment of radiation enteritis

目的 观察碱性成纤维细胞生长因子治疗放射性肠炎的临床疗效。方法 选取2015年9月至2018年2月本院放射性肠炎患者40例,随机分为观察组和对照组,各20例。在患者出现症状当日,对照组给予思密达3 g、维生素B12 7.5 mg、地塞米松注射液5 mg;治疗组在对照组基础上加用碱性成纤维细胞生长因子,两组均治疗28 d。治疗前后,评价观察两组临床疗效、卡氏评分(KPS)、症状积分,包括便血、腹痛、里急后重、大便性状及频率改变。结果 治疗后,观察组总有效率85.0%,明显高于对照组55.0%,差异有统计学意义(P<0.05);治疗后,观察组KPS评分(82.17±5.25)分,明显高于对照组(72.20±5.06)分,差异有统计学意义(P<0.05);治疗后,观察组腹痛、便血、里急后重、大便性状及频率、累计积分分别为(0.53±0.16)分、(0.30±0.04)分、(0.37±0.04)分、(0.33±0.04)分、(1.53±0.16)分,均低于对照组,差异均有统计学意义(均P<0.05)。结论 碱性成纤维细胞生长因子治疗放射性肠炎的疗效较好,值得深入研究。

Objective To observe the clinical efficacy of basic fibroblast growth factor in the treatment of radiation enteritis.Methods 40 patients with radiation enteritis treated at our hospital from September,2015 to February,2018 were selected and randomly divided into an observation group(n=20)and a control group(n=20).On the first day the symptoms occurred,the control group were treated with 3 g Smecta,7.5 mg vitamin B12,and 5 mg dexamethasone injection;in addition,the treatment group were treated with basic fibroblast growth factor;both groups were treated for 28 days.After the treatment,the clinical efficacies of the two groups were observed and evaluated.Before and after the treatment,the Kaposi scores(KPS)and the symptom scores,including hemafecia,abdominal pain,urgency,stool traits,and frequency changes,in the two groups were observed.Results After the treatment,the total effective rate and the KPS score were significantly higher in the observation group than in the control group[85.0% vs.55.0% and(82.17±5.25)vs.(72.20±5.06),both P<0.05].After the treatment,the scores of abdominal pain,hemafecia,urgency,and stool traits and frequency changes as well as the total score were(0.53±0.16),(0.30±0.04),(0.37±0.04),(0.33±0.04),and(1.53±0.16)in the observation group,which were lower than those in the control group(all P<0.05).Conclusion Basic fibroblast growth factor in the treatment of radiation enteritis is effective,so it is worth for further study.